A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Phase 2 Completed 40 enrolled Stichting European Myeloma Network Janssen Pharmaceutica · collab

NaSingle-groupOpen-labelTreatment

This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Subcutaneous
Subject	Daratumumab	Monoclonal antibody	16 mg/kg	Intravenous
Subject	Daratumumab	Monoclonal antibody	1800 mg	Intravenous
Subject	Dexamethasone	Small molecule	20 mg	Oral